The Fusion of Recombinant Proteins Has Resulted in Longer-Acting Therapeutics

By Iris Jacobs, MD

It’s difficult for most of us to fully appreciate what it’s like to have a rare disease caused by a deficient or defective protein. Traditionally, patients with certain types of protein deficiency or defect had no option other than to be intravenously injected two to three times per week with conventional therapies.

World PI Week

Teamwork: bringing rIX-FP to patients is a culmination of several years of work across the entire global organization. Seen here are members of CSL Behring’s rIX-FP Clinical Research and Development team in King of Prussia, Pa., U.S.

While frequent injections (prophylaxis) may prevent the onset of symptoms in most instances, this approach is a burden for patients who lead busy lives. It is also the main reason that routine prophylaxis is often delayed in young children. In addition, some symptoms can cause progressive and in certain patients debilitating damage.

Continue reading


Pivotal Data for Innovative Recombinant Therapies Unveiled at International Congress

Therapies that offer improved protection from bleeding with less frequent dosing
may soon be a reality for hemophilia patients.

July 16, 2015

By Andrew Cuthbertson, BMedSci, MBBS, Ph.D.

CSL Behring presented more than 20 abstracts last week at the International Society for Thrombosis and Haemostasis (ISTH) Congress in Toronto, Canada, including five oral presentations, from across our hematology portfolio of branded and investigational products.

CSL scientist

CSL scientist concentrates purified recombinant factor.

We are especially excited about pivotal data that we unveiled at the Congress for two of our late-stage, innovative recombinant products, the novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of hemophilia A, as well as the investigational long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP) for the treatment of hemophilia B. For both products, the data supported improved protection from bleeding with less frequent dosing without compromising the therapeutic benefit.

Our company has earned a reputation for delivering on its promises to our patients.

Our company has earned a reputation for delivering on its promises to our patients, helping people with life-threatening conditions live full lives. The latest milestones are significant advancements on our commitment as we continue to grow one of the industry’s largest portfolios of coagulation products that improve the care and well-being of patients around the world.
Continue reading

Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring.
This site is not intended as a forum for discussing CSL Behring or other companies' products.
Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.